| Not Yet Recruiting | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-As Metabolic Dysfunction-associated Steatohepatitis | Phase 1 | 2026-03-31 |
| Not Yet Recruiting | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | 2026-03-06 |
| Recruiting | The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Small for Gestational Age | Phase 3 | 2026-01-20 |
| Recruiting | The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature Idiopathic Short Stature | Phase 3 | 2025-04-28 |
| Completed | Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing Preeclampsia | Phase 1 | 2025-04-06 |
| Completed | Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females Preeclampsia | Phase 1 | 2025-03-26 |
| Completed | Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants Non-alcoholic Steatohepatitis | Phase 1 | 2025-03-06 |
| Recruiting | Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET Essential Thrombocythemia | Phase 2 | 2024-08-29 |
| Enrolling By Invitation | A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B Chronic Hepatitis B | N/A | 2022-03-18 |
| Completed | A Trial of YPEG-rhGH in Children With Short Stature Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome | Phase 2 | 2022-02-15 |
| Completed | A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease Renal Anemia of Chronic Kidney Disease | Phase 2 | 2021-03-12 |
| Completed | Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy Non-Myeloid Malignancy | Phase 3 | 2020-10-16 |
| Completed | A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B Chronic Hepatitis B | Phase 3 | 2019-12-04 |
| Completed | Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children Growth Hormone Deficiency | Phase 2 / Phase 3 | 2018-12-26 |
| Completed | Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy Hepatitis B | — | 2016-05-18 |
| Completed | A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B Chronic Hepatitis B | Phase 2 | 2014-06-01 |
| Completed | Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy Non Small Cell Lung Cancer, Breast Cancer | Phase 2 | 2013-12-01 |
| Completed | Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Chronic Hepatitis B | Phase 3 | 2013-03-01 |
| Completed | PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual Healthy | Phase 1 | 2012-09-01 |
| Completed | Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients Chronic Hepatitis C | Phase 3 | 2012-04-01 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteer Healthy | Phase 1 | 2011-01-01 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Su Healthy Subjects | Phase 1 | 2011-01-01 |
| Completed | Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C Chronic Hepatitis C | Phase 2 | 2010-07-01 |
| Completed | Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Chronic Hepatitis B | Phase 2 | 2010-07-01 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients Chemotherapy Patients | Phase 1 | 2010-04-01 |
| Completed | Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Al Mycoses | Phase 4 | 2009-09-01 |